CELG – Celgene Corporation – Fundamental analysis, financial statements, key ratios, and fair value analysis

Celgene Corporation

Healthcare
Biotechnology
84.9
4.47
5.56%
106.0
59.21
Stock Current Price
Change
Change %
52 Week High
52 Week Low

Financial Ratios

Earnings per Share (EPS)3.84
EPS Estimate Currrent Qtr2.08
Book Value Per Share6.95
Market Cap 59 Billion
PE Ratio 15.8
Dividend YieldNA

Stock Yield

Stock Return 7 Days5.44%
Stock Return 15 Days-8.37%
Stock Return 30 Days -14.97%
Stock Return 3 Months-32.04%
Stock Return One Year-41.19%
Stock Return 3 Years-39.63%

Stock Technical Analysis

Relative Strengh Index (14)64.15
Average True Range (14)4.08
Momentum (14)9.53
Simple Moving Average (14) 9.53
Time Series Forecast (14)59.95
Time Series Forecast (30) 72.78

Stock News

NewsSourcePublished
Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for CelgeneYahoo Finance01/06/2019 23:15
2019 J.P. Morgan Healthcare Conference RoundupYahoo Finance01/06/2019 16:00
All the Pre-JPM News Healthcare Investors Need to KnowYahoo Finance01/06/2019 15:00
The Week Ahead In Biotech: Conferences, Clinical TrialsYahoo Finance01/06/2019 14:16
See what the IHS Markit Score report has to say about Celgene Corp.Yahoo Finance01/05/2019 13:06
Celgene invests additional $30M in NantCellSeeking Alpha01/04/2019 19:52
Celgene: Still Upside Left After Deal?Seeking Alpha01/04/2019 16:32
Bristol To Become Top 5 Pharma — And Other Fallout From Celgene TakeoverYahoo Finance01/04/2019 21:24
Bristol-Myers Buys Celgene: Smart Plan Or A Rush To Action?Seeking Alpha01/04/2019 16:16
Stock Market Rally Extends On Fed Chairman Powell, Jobs; Apple, Tesla, Delta Disappoint; Bristol-Myers Buys Celgene: Weekly ReviewYahoo Finance01/04/2019 21:06
CELGENE CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of MergerYahoo Finance01/04/2019 18:46
What to Expect from BMY’s Celgene AcquisitionYahoo Finance01/04/2019 18:35
Manufacturing, Apple, & Jobs: This Week’s Top Market StoriesYahoo Finance01/04/2019 18:31
Biotechs lead broad market advance, XBI up 5%Seeking Alpha01/04/2019 13:11
Here's Why bluebird bio Shares Got Knocked Down 19.3% in DecemberYahoo Finance01/04/2019 17:16
How Celgene Is Positioned NowYahoo Finance01/04/2019 17:05
Celgene hiked prices for Revlimid and Otezla on same day as merger announcementSeeking Alpha01/04/2019 12:02
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Celgene Corporation to Bristol-Myers Squibb Company is Fair to ShareholdersYahoo Finance01/04/2019 16:32

Financial Statements

index2014201520162017
Revenue8 Billion9 Billion11 Billion13 Billion
Cost of Revenue386 Million420 Million438 Million461 Million
Gross Profit7 Billion9 Billion11 Billion13 Billion
Gross Margin (%)94.97%95.46%96.10%96.45%
Selling General and Administrative Expense2 Billion2 Billion3 Billion3 Billion
Other operating expenses3 Billion4 Billion5 Billion5 Billion
Earning Before Interest and Taxes EBIT3 Billion2 Billion3 Billion5 Billion
EBIT/Operating Margin (%)32.64%25.22%25.58%37.19%
Interest Expense176 Million311 Million500 Million522 Million
Other non-operating expenses/income0000
Earnings before Tax2 Billion2 Billion2 Billion4 Billion
Income Tax Expense328 Million421 Million373 Million1 Billion
Net Income2 Billion2 Billion2 Billion3 Billion
Net Margin (%)26.07%17.31%17.80%22.61%
Earnings per share from operating income0.5237710.7509940.5769950.451895
Earnings per Diluted Share2.391.942.493.64
Dividends per Basic Common Share0000
Weighted average number of shares outstanding837 Million826 Million803 Million808 Million
index2017 Q42018 Q12018 Q22018 Q3
Revenue3 Billion4 Billion4 Billion4 Billion
Cost of Revenue119 Million135 Million126 Million157 Million
Gross Profit3 Billion3 Billion4 Billion4 Billion
Gross Margin (%)96.58%96.18%96.70%95.97%
Selling General and Administrative Expense774 Million864 Million790 Million746 Million
Other operating expenses1 Billion1 Billion1 Billion1 Billion
Earning Before Interest and Taxes EBIT1 Billion1 Billion1 Billion2 Billion
EBIT/Operating Margin (%)36.55%33.80%39.30%40.36%
Interest Expense142 Million166 Million192 Million193 Million
Other non-operating expenses/income0000
Earnings before Tax1 Billion1 Billion1 Billion1 Billion
Income Tax Expense1 Billion184 Million262 Million296 Million
Net Income-81 Million846 Million1 Billion1 Billion
Net Margin (%)-0.00%23.91%27.40%27.80%
Earnings per share from operating income196.4511.285191.003110.967961
Earnings per Diluted Share-01.11.431.5
Dividends per Basic Common Share0000
Weighted average number of shares outstanding1 Billion769 Million731 Million721 Million
index2014201520162017
Cash and Equivalents4 Billion5 Billion6 Billion7 Billion
Trade and Non Trade Receivables1 Billion1 Billion2 Billion2 Billion
Inventory393 Million443 Million498 Million541 Million
Other current assets12 Billion12 Billion15 Billion19 Billion
Current Assets10 Billion9 Billion11 Billion15 Billion
Total Non-Current Assets8 Billion18 Billion17 Billion15 Billion
Total Assets17 Billion27 Billion28 Billion30 Billion
Trade and Non Trade Payables198 Million241 Million247 Million305 Million
Other current liabilities2 Billion2 Billion3 Billion3 Billion
Current Liabilities2 Billion2 Billion3 Billion3 Billion
Liabilities Non Current9 Billion19 Billion19 Billion20 Billion
Accumulated Retained Earnings Deficit6 Billion8 Billion10 Billion13 Billion
Shareholder’s equity other52 Million-2 Billion-3 Billion-6 Billion
Shareholders Equity7 Billion6 Billion7 Billion7 Billion
Noncontrolling interests4 Billion4 Billion6 Billion6 Billion
Total Assets17 Billion27 Billion28 Billion30 Billion
index2017 Q42018 Q12018 Q22018 Q3
Cash and Equivalents7 Billion3 Billion2 Billion2 Billion
Trade and Non Trade Receivables2 Billion2 Billion2 Billion2 Billion
Inventory541 Million536 Million555 Million510 Million
Other current assets19 Billion8 Billion6 Billion8 Billion
Current Assets15 Billion8 Billion7 Billion8 Billion
Total Non-Current Assets15 Billion27 Billion27 Billion26 Billion
Total Assets30 Billion35 Billion33 Billion34 Billion
Trade and Non Trade Payables305 Million320 Million294 Million292 Million
Other current liabilities3 Billion3 Billion4 Billion3 Billion
Current Liabilities3 Billion3 Billion5 Billion4 Billion
Liabilities Non Current20 Billion26 Billion26 Billion26 Billion
Accumulated Retained Earnings Deficit13 Billion14 Billion15 Billion16 Billion
Shareholder’s equity other-6 Billion-9 Billion-12 Billion-12 Billion
Shareholders Equity7 Billion5 Billion3 Billion5 Billion
Noncontrolling interests6 Billion6 Billion9 Billion7 Billion
Total Assets30 Billion35 Billion33 Billion34 Billion
index2014201520162017
Net Cash Flow from Operations3 Billion3 Billion4 Billion5 Billion
Capital Expenditure-150 Million-286 Million-236 Million-279 Million
Net Cash Flow from Investing-1 Billion-6 Billion-1 Billion-3 Billion
Net Cash Flow from Financing-417 Million4 Billion-2 Billion-2 Billion
Cash and Equivalents4 Billion5 Billion6 Billion7 Billion
index2017 Q42018 Q12018 Q22018 Q3
Net Cash Flow from Operations2 Billion-325 Million1 Billion2 Billion
Capital Expenditure-103 Million-88 Million-80 Million-64 Million
Net Cash Flow from Investing1 Billion-6 Billion-128 Million-31 Million
Net Cash Flow from Financing-1 Billion2 Billion-2 Billion-913 Million
Cash and Equivalents7 Billion3 Billion2 Billion2 Billion

Stock Price History

table